Hill Holliday Health launches inside its Boston-based parent agency

Hill Holliday Health launches with executive creative director David Leonardi and managing director Scott Rabschnuk at the helm. (Business Wire)

Boston ad agency Hill Holliday has been doing pharma and healthcare work for years. But not many people seemed to know about it. So last week, the agency created a health-specific branded agency within itself with the launch of Hill Holliday Health.

The agency made a conscious decision years ago to not brand as a healthcare agency in order to stand out with its consumer approach in the busy healthcare marketing arena, managing director Scott Rabschnuk explained. But more recently, Hill Holliday discovered that, especially when it came to recruiting health marketing talent, people would say they “didn’t even know you guys did healthcare."

RELATED: FCB Health launches stand-alone agency for pharma and healthcare branding

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

“We realized we weren’t on the radar, so we were having a hard time attracting talent and we probably weren’t getting our fair share of at-bats with clients,” he said. “We can still be that consumer-oriented healthcare organization and our work speaks for itself, but we need to brand ourselves and give ourselves an identity so that both prospective clients as well as great industry talent, knows we’re on the map.”

The 120-person workforce of Hill Holliday Health will continue its work for pharma clients such as Novartis and Johnson & Johnson’s Janssen for brands Xarelto and Invokana, as well as pitch for new business and look to hire more healthcare talent.

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…

A North Carolina federal jury found that Puma maliciously defamed Eshelman amid a proxy fight that began in late 2015.